Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Dow
Baxter
Mallinckrodt
Express Scripts

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR RUFINAMIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Rufinamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00334958 ↗ Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures Completed Eisai Inc. Phase 3 2006-02-13 To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).
NCT00448539 ↗ Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures Terminated Eisai Inc. Phase 3 2007-03-15 This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301. The main objective of this study was to evaluate the safety and efficacy of long-term administration of rufinamide for the control of epileptic seizures in participants who had refractory partial seizures despite treatment with a maximum of three approved antiepileptic drugs (AEDs).
NCT00595231 ↗ Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD) Completed INC Research Phase 2 2008-03-01 A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rufinamide

Condition Name

Condition Name for Rufinamide
Intervention Trials
Lennox-Gastaut Syndrome 4
Epilepsy 2
Refractory Partial Seizures 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rufinamide
Intervention Trials
Lennox Gastaut Syndrome 4
Seizures 4
Syndrome 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rufinamide

Trials by Country

Trials by Country for Rufinamide
Location Trials
United States 66
Japan 39
Italy 5
Canada 3
Switzerland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rufinamide
Location Trials
Ohio 4
Georgia 4
New Hampshire 3
Illinois 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rufinamide

Clinical Trial Phase

Clinical Trial Phase for Rufinamide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 6
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rufinamide
Clinical Trial Phase Trials
Completed 7
Withdrawn 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rufinamide

Sponsor Name

Sponsor Name for Rufinamide
Sponsor Trials
Eisai Inc. 3
Eisai Co., Ltd. 2
University of Zurich 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rufinamide
Sponsor Trials
Other 23
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Merck
Mallinckrodt
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.